Enzymatica has partnered with Esteve, a leading pharmaceutical company in Spain. The agreement provides Esteve with exclusive rights to sell, market and distribute ColdZyme to pharmacies in Spain and Andorra. The product launch is scheduled for January 2016.
The agreement covers Enzymatica's products ColdZyme 20 ml and ColdZyme One Cold, 7 ml. In Spain the products will be sold under the co-brand Cortagrip/ColdZyme.
"The agreement with Esteve is a first step in our strategy to expand outside the Nordic region through strong commercial partners. Esteve is a well-established pharmaceutical company with strong presence on the Spanish market and acknowledged experience of launching new products, which will favor the introduction of ColdZyme in Spain", says Fredrik Lindberg, CEO of Enzymatica.
Esteve is one of the top ten companies in the Spanish pharmaceutical market, with full market access and covering more than 21,000 pharmacies.
"The agreement with Enzymatica is an important part of our strategic plan to increase our presence in the cold and flu segment through innovative products. ColdZyme® is unique in its mode of action, working on the cause of a common cold instead of just treating the symptoms", says Gemma Barzano, Director of Consumer Care at Esteve.
Spain is one of the five largest markets for OTC cold and flu products within the EU. In 2012 the value was over 500 million USD.
ColdZyme is currently sold directly by Enzymatica in Sweden, Norway and Denmark and through a contract organization in the UK. The products are registered as medical devices at the Swedish Medical Products Agency, allowing marketing and sales in Sweden and other countries within the EEA.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on four markets. The product became the leading article for colds in Swedish pharmacies in winter 2014-2015. Development includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com .
Erik Penser Bankaktiebolag is Certified Adviser for Enzymatica.
About Esteve ESTEVE ( www.esteve.com ) is a chemical - pharmaceutical group leader in Spain and with a significant international presence. Founded in 1929 and chaired by Joan Esteve, it currently employs about 2,300 people. It has affiliate companies and industrial facilities in Europe, USA, Mexico and China. Total sales in 2014 reached 838 million euros.
The company maintains a strong commitment to excellence, devoting all its efforts to promote health and improve quality of life. Research is the hallmark of ESTEVE, which has a portfolio of highly innovative projects whose ultimate goal is to provide answers to medical needs not covered properly.
HUG#1966126
